North American Business Development Opportunities

Benefits of Partnering with Apotex

Apotex is a leader in the North American generic pharmaceutical market with #1 ranking in Canada in terms of prescriptions filled, sales volume and value, and a Top 10 position in the U.S.A.

We are a vertically integrated company. Our preference is to develop, manufacture and market our own products — from API to finished dosage form to marketing and distribution.

Apotex does however have an interest in complimenting its own product portfolio/pipeline with products from third parties where they can offer:

• Early to market opportunities
• Dosage Forms Apotex does not manufacture

Examples of our successful collaboration with third parties:

• Partnership with Orchid Chemicals & Pharmaceuticals Ltd. for cephalosporin injectables for the U.S.A. and Canadian markets
• First to launch Cefepime injection; collaboration with Orchid Chemicals & Pharmaceuticals Ltd.
• First to launch a generic oral contraceptive product in Canada (Portia®); collaboration with Barr Pharmaceuticals, Inc.

Early to market opportunities

• first-to-file
• non-infringing API and/or formulations

Apotex has substantial experience in identifying, developing, registering and defending litigation in early to market opportunities, including Para IV opportunities.

Examples of our recent early to market activities:

• Apotex Invalidates Norvasc® Patent
• Apotex Launches First Generic Plavix®

Dosage Forms Apotex does not manufacture:

For Dosage Forms where there is an opportunity for Apotex to contribute to Formulation, Analytical Development or Clinical Development, Apotex is interested in Co-Development.